

**HPTN 084 – A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women**  
**Atlas Open Report – March 5, 2024**  
**Visit Cutoff Date: March 5, 2024**  
**Table 8 – Retention <sup>2</sup> by Visit and Site**

	<b>Overall</b>	<b>Botswana: Gaborone: Gaborone CRS</b>	<b>Kenya: Kisumu: Kisumu CRS</b>	<b>Malawi: Blantyre: Blantyre CRS</b>	<b>Malawi: Lilongwe: Malawi CRS</b>	<b>South Africa: Botha's Hill: Botha's Hill CRS</b>	<b>South Africa: Cape Town: Emavundleni CRS</b>
Total Participants Enrolled <sup>1</sup>	3224	91	66	113	111	223	223
<b>Step 1</b>							
Week 2	3068/3212 (95.5%)	85/91 (93.4%)	65/66 (98.5%)	108/113 (95.6%)	107/109 (98.2%)	218/222 (98.2%)	214/223 (96.0%)
Week 4	3137/3197 (98.1%)	84/87 (96.6%)	65/66 (98.5%)	112/113 (99.1%)	108/109 (99.1%)	222/222 (100.0%)	216/222 (97.3%)
<b>Step 2</b>							
Participants entering Step 2 <sup>3</sup>	3058/3063 (99.8%)	80/80 (100.0%)	64/65 (98.5%)	112/112 (100.0%)	105/105 (100.0%)	218/218 (100.0%)	210/210 (100.0%)
Week 6 Safety Visit	2933/3063 (95.8%)	76/80 (95.0%)	63/65 (96.9%)	112/112 (100.0%)	104/105 (99.0%)	208/218 (95.4%)	196/210 (93.3%)
Week 9 (Injection #2)	2935/3061 (95.9%)	76/80 (95.0%)	55/65 (84.6%)	112/112 (100.0%)	101/104 (97.1%)	195/218 (89.4%)	204/210 (97.1%)
Week 13 Safety Visit	2797/3053 (91.6%)	71/79 (89.9%)	58/65 (89.2%)	108/111 (97.3%)	99/104 (95.2%)	204/217 (94.0%)	181/210 (86.2%)
Week 17 (Injection #3)	2872/3047 (94.3%)	73/78 (93.6%)	48/64 (75.0%)	109/111 (98.2%)	97/103 (94.2%)	210/217 (96.8%)	196/210 (93.3%)
Week 21 Safety Visit	2764/3037 (91.0%)	73/77 (94.8%)	59/64 (92.2%)	107/111 (96.4%)	94/103 (91.3%)	201/216 (93.1%)	189/210 (90.0%)
Week 25 (Injection #4)	2836/3029 (93.6%)	73/76 (96.1%)	62/64 (96.9%)	108/111 (97.3%)	93/103 (90.3%)	205/216 (94.9%)	198/209 (94.7%)
Week 33 (Injection #5)	2796/3013 (92.8%)	72/76 (94.7%)	60/64 (93.8%)	107/111 (96.4%)	95/103 (92.2%)	197/214 (92.1%)	196/208 (94.2%)
Week 41 (Injection #6)	2606/2996 (87.0%)	67/76 (88.2%)	60/64 (93.8%)	99/111 (89.2%)	86/101 (85.1%)	185/214 (86.4%)	186/207 (89.9%)
Week 42 Safety Visit	2496/2977 (83.8%)	66/75 (88.0%)	61/64 (95.3%)	62/111 (55.9%)	86/98 (87.8%)	184/209 (88.0%)	151/207 (72.9%)
Week 49 (Injection #7)	2695/2970 (90.7%)	72/74 (97.3%)	60/64 (93.8%)	103/111 (92.8%)	89/98 (90.8%)	185/209 (88.5%)	182/207 (87.9%)
Week 57 (Injection #8)	2642/2955 (89.4%)	69/72 (95.8%)	60/64 (93.8%)	98/109 (89.9%)	84/97 (86.6%)	182/206 (88.3%)	180/207 (87.0%)
Week 65 (Injection #9)	2594/2942 (88.2%)	68/71 (95.8%)	62/64 (96.9%)	97/108 (89.8%)	80/97 (82.5%)	186/204 (91.2%)	182/206 (88.3%)
Week 73 (Injection #10)	2505/2920 (85.8%)	66/70 (94.3%)	61/63 (96.8%)	94/108 (87.0%)	76/95 (80.0%)	187/202 (92.6%)	179/204 (87.7%)
Week 81 (Injection #11)	2436/2909 (83.7%)	65/69 (94.2%)	60/63 (95.2%)	91/108 (84.3%)	74/95 (77.9%)	188/197 (95.4%)	166/204 (81.4%)
Week 89 (Injection #12)	2281/2885 (79.1%)	66/68 (97.1%)	58/61 (95.1%)	87/107 (81.3%)	71/93 (76.3%)	171/193 (88.6%)	150/203 (73.9%)
Week 97 (Injection #13)	2197/2867 (76.6%)	64/66 (97.0%)	57/61 (93.4%)	86/106 (81.1%)	67/91 (73.6%)	160/192 (83.3%)	146/203 (71.9%)
Week 105 (Injection #14)	2129/2845 (74.8%)	61/65 (93.8%)	54/59 (91.5%)	85/105 (81.0%)	60/90 (66.7%)	160/192 (83.3%)	143/200 (71.5%)
Week 113 (Injection #15)	1962/2769 (70.9%)	61/63 (96.8%)	53/59 (89.8%)	84/105 (80.0%)	60/87 (69.0%)	143/187 (76.5%)	121/197 (61.4%)
Week 121 (Injection #16)	1834/2649 (69.2%)	59/62 (95.2%)	52/57 (91.2%)	83/104 (79.8%)	54/86 (62.8%)	125/165 (75.8%)	117/179 (65.4%)
Week 129 (Injection #17)	1630/2629 (62.0%)	52/61 (85.2%)	53/57 (93.0%)	76/103 (73.8%)	45/86 (52.3%)	115/165 (69.7%)	98/177 (55.4%)
Week 137 (Injection #18)	1379/2585 (53.3%)	41/61 (67.2%)	52/56 (92.9%)	75/103 (72.8%)	30/85 (35.3%)	96/163 (58.9%)	82/174 (47.1%)
Week 145 (Injection #19)	1114/2441 (45.6%)	33/60 (55.0%)	47/56 (83.9%)	71/103 (68.9%)	19/84 (22.6%)	74/137 (54.0%)	65/155 (41.9%)
Week 153 (Injection #20)	866/2290 (37.8%)	24/60 (40.0%)	32/55 (58.2%)	59/102 (57.8%)	13/83 (15.7%)	55/125 (44.0%)	43/144 (29.9%)
Week 161 (Injection #21)	640/2036 (31.4%)	20/55 (36.4%)	15/55 (27.3%)	47/97 (48.5%)	5/77 (6.5%)	43/112 (38.4%)	19/133 (14.3%)
Week 169 (Injection #22)	434/1689 (25.7%)	15/48 (31.3%)	8/55 (14.5%)	28/80 (35.0%)	1/56 (1.8%)	28/90 (31.1%)	9/120 (7.5%)

<sup>1</sup> Inappropriately enrolled participants are excluded.

<sup>2</sup> Retention at a visit is defined as the number (and %) of participants who completed the visit divided by the number of participants who are expected (visit window has closed), plus any participants who have completed the visit prior to their window closure. The denominator includes participants who are alive, HIV uninfected and have not permanently discontinued study product at the time of the visit.

**HPTN 084 – A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women**  
**Atlas Open Report – March 5, 2024**  
**Visit Cutoff Date: March 5, 2024**  
**Table 8 – Retention <sup>2</sup> by Visit and Site**

	<b>South Africa: Cape Town: Stellenbosch University (DTTC-SU) CRS</b>	<b>South Africa: Johannesburg: Ward 21</b>	<b>South Africa: Kwa Zulu Natal: Isipingo CRS</b>	<b>South Africa: Kwa Zulu Natal: Verulam CRS</b>	<b>South Africa: Soweto: Soweto HPTN CRS</b>	<b>Swaziland: Siteki: Swaziland Prevention Center</b>	<b>Uganda: Entebbe: UVRI-IAVI</b>
Total Participants Enrolled <sup>1</sup>	159	206	170	151	176	160	182
<b>Step 1</b>							
Week 2	118/158 (74.7%)	203/205 (99.0%)	164/168 (97.6%)	138/151 (91.4%)	170/173 (98.3%)	151/160 (94.4%)	176/182 (96.7%)
Week 4	149/157 (94.9%)	199/203 (98.0%)	167/168 (99.4%)	144/150 (96.0%)	171/173 (98.8%)	158/160 (98.8%)	178/181 (98.3%)
<b>Step 2</b>							
Participants entering Step 2 <sup>3</sup>	141/141 (100.0%)	197/197 (100.0%)	162/162 (100.0%)	140/141 (99.3%)	169/169 (100.0%)	150/150 (100.0%)	175/175 (100.0%)
Week 6 Safety Visit	98/141 (69.5%)	193/197 (98.0%)	155/162 (95.7%)	131/141 (92.9%)	168/169 (99.4%)	148/150 (98.7%)	173/175 (98.9%)
Week 9 (Injection #2)	126/141 (89.4%)	191/197 (97.0%)	153/162 (94.4%)	132/141 (93.6%)	166/169 (98.2%)	149/150 (99.3%)	168/174 (96.6%)
Week 13 Safety Visit	84/139 (60.4%)	190/196 (96.9%)	151/162 (93.2%)	134/141 (95.0%)	162/169 (95.9%)	146/150 (97.3%)	139/173 (80.3%)
Week 17 (Injection #3)	119/139 (85.6%)	190/195 (97.4%)	157/161 (97.5%)	131/141 (92.9%)	165/169 (97.6%)	147/150 (98.0%)	167/173 (96.5%)
Week 21 Safety Visit	81/139 (58.3%)	186/194 (95.9%)	155/160 (96.9%)	127/140 (90.7%)	165/169 (97.6%)	143/149 (96.0%)	147/173 (85.0%)
Week 25 (Injection #4)	122/139 (87.8%)	182/191 (95.3%)	148/160 (92.5%)	129/140 (92.1%)	167/168 (99.4%)	140/149 (94.0%)	161/172 (93.6%)
Week 33 (Injection #5)	119/138 (86.2%)	174/188 (92.6%)	140/160 (87.5%)	131/139 (94.2%)	163/167 (97.6%)	138/147 (93.9%)	157/171 (91.8%)
Week 41 (Injection #6)	99/138 (71.7%)	164/187 (87.7%)	133/159 (83.6%)	116/139 (83.5%)	159/163 (97.5%)	134/146 (91.8%)	138/169 (81.7%)
Week 42 Safety Visit	52/137 (38.0%)	166/186 (89.2%)	153/159 (96.2%)	125/139 (89.9%)	124/162 (76.5%)	132/146 (90.4%)	136/169 (80.5%)
Week 49 (Injection #7)	108/137 (78.8%)	165/184 (89.7%)	154/158 (97.5%)	134/139 (96.4%)	158/162 (97.5%)	137/146 (93.8%)	149/169 (88.2%)
Week 57 (Injection #8)	109/136 (80.1%)	162/183 (88.5%)	146/156 (93.6%)	132/139 (95.0%)	155/162 (95.7%)	131/146 (89.7%)	150/168 (89.3%)
Week 65 (Injection #9)	103/136 (75.7%)	155/183 (84.7%)	148/156 (94.9%)	129/139 (92.8%)	152/162 (93.8%)	132/146 (90.4%)	138/166 (83.1%)
Week 73 (Injection #10)	100/134 (74.6%)	138/182 (75.8%)	149/154 (96.8%)	125/139 (89.9%)	147/162 (90.7%)	128/144 (88.9%)	127/165 (77.0%)
Week 81 (Injection #11)	91/133 (68.4%)	134/181 (74.0%)	146/153 (95.4%)	129/139 (92.8%)	137/162 (84.6%)	125/144 (86.8%)	121/165 (73.3%)
Week 89 (Injection #12)	81/133 (60.9%)	128/180 (71.1%)	121/151 (80.1%)	116/139 (83.5%)	133/161 (82.6%)	113/143 (79.0%)	105/162 (64.8%)
Week 97 (Injection #13)	83/133 (62.4%)	122/179 (68.2%)	113/151 (74.8%)	103/139 (74.1%)	130/158 (82.3%)	113/142 (79.6%)	101/161 (62.7%)
Week 105 (Injection #14)	86/132 (65.2%)	117/179 (65.4%)	111/150 (74.0%)	96/137 (70.1%)	127/157 (80.9%)	107/138 (77.5%)	98/161 (60.9%)
Week 113 (Injection #15)	61/124 (49.2%)	117/168 (69.6%)	105/136 (77.2%)	91/128 (71.1%)	124/145 (85.5%)	89/134 (66.4%)	85/160 (53.1%)
Week 121 (Injection #16)	55/118 (46.6%)	105/153 (68.6%)	95/116 (81.9%)	83/110 (75.5%)	122/142 (85.9%)	84/125 (67.2%)	71/158 (44.9%)
Week 129 (Injection #17)	51/113 (45.1%)	94/153 (61.4%)	92/114 (80.7%)	72/108 (66.7%)	106/141 (75.2%)	71/124 (57.3%)	56/158 (35.4%)
Week 137 (Injection #18)	40/109 (36.7%)	77/150 (51.3%)	71/111 (64.0%)	59/99 (59.6%)	98/139 (70.5%)	50/122 (41.0%)	37/158 (23.4%)
Week 145 (Injection #19)	30/88 (34.1%)	65/138 (47.1%)	33/103 (32.0%)	45/92 (48.9%)	92/138 (66.7%)	19/114 (16.7%)	34/149 (22.8%)
Week 153 (Injection #20)	22/80 (27.5%)	58/135 (43.0%)	19/93 (20.4%)	28/85 (32.9%)	77/135 (57.0%)	11/96 (11.5%)	28/121 (23.1%)
Week 161 (Injection #21)	14/72 (19.4%)	46/125 (36.8%)	16/79 (20.3%)	24/68 (35.3%)	56/120 (46.7%)	7/79 (8.9%)	21/100 (21.0%)
Week 169 (Injection #22)	10/61 (16.4%)	37/111 (33.3%)	13/47 (27.7%)	16/53 (30.2%)	50/109 (45.9%)	1/63 (1.6%)	16/76 (21.1%)

<sup>1</sup> Inappropriately enrolled participants are excluded.

<sup>2</sup> Retention at a visit is defined as the number (and %) of participants who completed the visit divided by the number of participants who are expected (visit window has closed), plus any participants who have completed the visit prior to their window closure. The denominator includes participants who are alive, HIV uninfected and have not permanently discontinued study product at the time of the visit.

Source: SCHARP (Anusha) – /trials/hptn/p084/analysis/atlas/code/open/t\_retention.sas, SAS Version 9.4 (05MAR2024,19:59)

**HPTN 084 – A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women**  
**Atlas Open Report – March 5, 2024**  
**Visit Cutoff Date: March 5, 2024**  
**Table 8 – Retention <sup>2</sup> by Visit and Site**

	<b>Uganda: Kampala: Baylor-Uganda CRS</b>	<b>Uganda: Kampala: MU-JHU Research Collaboration CRS</b>	<b>Zimbabwe: Chitungwiza: Seke South CRS</b>	<b>Zimbabwe: Chitungwiza: St.Mary's CRS</b>	<b>Zimbabwe: Chitungwiza: Zengeza CRS</b>	<b>Zimbabwe: Harare: Parirenyatwa CRS</b>	<b>Zimbabwe: Harare: Spilhaus CRS</b>
Total Participants Enrolled <sup>1</sup>	210	204	160	166	162	153	138
<b>Step 1</b>							
Week 2	201/210 (95.7%)	198/204 (97.1%)	153/160 (95.6%)	157/166 (94.6%)	162/162 (100.0%)	145/153 (94.8%)	135/136 (99.3%)
Week 4	202/209 (96.7%)	198/202 (98.0%)	153/160 (95.6%)	166/166 (100.0%)	160/162 (98.8%)	150/152 (98.7%)	135/135 (100.0%)
<b>Step 2</b>							
Participants entering Step 2 <sup>3</sup>	192/194 (99.0%)	190/190 (100.0%)	152/152 (100.0%)	160/161 (99.4%)	159/159 (100.0%)	148/148 (100.0%)	134/134 (100.0%)
Week 6 Safety Visit	188/194 (96.9%)	184/190 (96.8%)	151/152 (99.3%)	155/161 (96.3%)	159/159 (100.0%)	137/148 (92.6%)	134/134 (100.0%)
Week 9 (Injection #2)	184/194 (94.8%)	185/190 (97.4%)	147/152 (96.7%)	153/161 (95.0%)	158/159 (99.4%)	147/148 (99.3%)	133/134 (99.3%)
Week 13 Safety Visit	178/194 (91.8%)	172/190 (90.5%)	142/152 (93.4%)	147/160 (91.9%)	154/159 (96.9%)	146/148 (98.6%)	131/134 (97.8%)
Week 17 (Injection #3)	174/194 (89.7%)	172/189 (91.0%)	144/152 (94.7%)	148/160 (92.5%)	152/159 (95.6%)	143/148 (96.6%)	130/134 (97.0%)
Week 21 Safety Visit	166/194 (85.6%)	162/187 (86.6%)	141/152 (92.8%)	144/159 (90.6%)	149/158 (94.3%)	145/148 (98.0%)	130/134 (97.0%)
Week 25 (Injection #4)	167/194 (86.1%)	175/187 (93.6%)	139/152 (91.4%)	146/159 (91.8%)	149/158 (94.3%)	144/148 (97.3%)	128/133 (96.2%)
Week 33 (Injection #5)	160/193 (82.9%)	179/186 (96.2%)	140/152 (92.1%)	150/159 (94.3%)	147/158 (93.0%)	144/147 (98.0%)	127/132 (96.2%)
Week 41 (Injection #6)	140/193 (72.5%)	159/185 (85.9%)	136/152 (89.5%)	133/157 (84.7%)	144/157 (91.7%)	140/146 (95.9%)	128/132 (97.0%)
Week 42 Safety Visit	148/192 (77.1%)	161/183 (88.0%)	135/150 (90.0%)	142/155 (91.6%)	145/157 (92.4%)	140/146 (95.9%)	127/132 (96.2%)
Week 49 (Injection #7)	150/191 (78.5%)	165/182 (90.7%)	136/149 (91.3%)	139/155 (89.7%)	144/157 (91.7%)	138/146 (94.5%)	127/132 (96.2%)
Week 57 (Injection #8)	144/191 (75.4%)	161/181 (89.0%)	134/149 (89.9%)	142/155 (91.6%)	138/156 (88.5%)	139/146 (95.2%)	126/132 (95.5%)
Week 65 (Injection #9)	141/191 (73.8%)	164/178 (92.1%)	127/147 (86.4%)	133/154 (86.4%)	136/156 (87.2%)	134/146 (91.8%)	127/132 (96.2%)
Week 73 (Injection #10)	136/191 (71.2%)	157/175 (89.7%)	115/145 (79.3%)	133/153 (86.9%)	134/156 (85.9%)	129/146 (88.4%)	124/132 (93.9%)
Week 81 (Injection #11)	131/191 (68.6%)	147/174 (84.5%)	114/144 (79.2%)	129/153 (84.3%)	132/156 (84.6%)	131/146 (89.7%)	125/132 (94.7%)
Week 89 (Injection #12)	130/191 (68.1%)	145/173 (83.8%)	108/144 (75.0%)	125/153 (81.7%)	130/156 (83.3%)	124/142 (87.3%)	119/132 (90.2%)
Week 97 (Injection #13)	125/191 (65.4%)	139/170 (81.8%)	106/144 (73.6%)	124/153 (81.0%)	126/154 (81.8%)	117/141 (83.0%)	115/132 (87.1%)
Week 105 (Injection #14)	123/191 (64.4%)	135/169 (79.9%)	104/144 (72.2%)	120/152 (78.9%)	121/153 (79.1%)	106/140 (75.7%)	115/131 (87.8%)
Week 113 (Injection #15)	109/190 (57.4%)	119/169 (70.4%)	99/145 (68.3%)	111/149 (74.5%)	120/152 (78.9%)	103/140 (73.6%)	107/131 (81.7%)
Week 121 (Injection #16)	98/190 (51.6%)	106/168 (63.1%)	91/144 (63.2%)	106/149 (71.1%)	118/152 (77.6%)	104/140 (74.3%)	106/131 (80.9%)
Week 129 (Injection #17)	79/188 (42.0%)	69/166 (41.6%)	80/143 (55.9%)	104/149 (69.8%)	113/152 (74.3%)	101/140 (72.1%)	103/131 (78.6%)
Week 137 (Injection #18)	67/182 (36.8%)	56/160 (35.0%)	68/142 (47.9%)	92/149 (61.7%)	102/151 (67.5%)	96/140 (68.6%)	90/131 (68.7%)
Week 145 (Injection #19)	56/168 (33.3%)	51/145 (35.2%)	51/142 (35.9%)	74/149 (49.7%)	94/150 (62.7%)	85/139 (61.2%)	76/131 (58.0%)
Week 153 (Injection #20)	49/145 (33.8%)	37/128 (28.9%)	35/139 (25.2%)	61/149 (40.9%)	80/147 (54.4%)	79/139 (56.8%)	56/129 (43.4%)
Week 161 (Injection #21)	30/125 (24.0%)	29/85 (34.1%)	28/121 (23.1%)	51/144 (35.4%)	66/144 (45.8%)	61/133 (45.9%)	42/112 (37.5%)
Week 169 (Injection #22)	17/99 (17.2%)	20/73 (27.4%)	14/82 (17.1%)	32/119 (26.9%)	50/131 (38.2%)	43/123 (35.0%)	26/93 (28.0%)

<sup>1</sup> Inappropriately enrolled participants are excluded.

<sup>2</sup> Retention at a visit is defined as the number (and %) of participants who completed the visit divided by the number of participants who are expected (visit window has closed), plus any participants who have completed the visit prior to their window closure. The denominator includes participants who are alive, HIV uninfected and have not permanently discontinued study product at the time of the visit.

**HPTN 084 – A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women**  
**Atlas Open Report – March 5, 2024**  
**Visit Cutoff Date: March 5, 2024**  
**Table 8 – Retention <sup>2</sup> by Visit and Site**

	<b>Overall</b>	<b>Botswana: Gaborone: Gaborone CRS</b>	<b>Kenya: Kisumu: Kisumu CRS</b>	<b>Malawi: Blantyre: Blantyre CRS</b>	<b>Malawi: Lilongwe: Malawi CRS</b>	<b>South Africa: Botha's Hill: Botha's Hill CRS</b>	<b>South Africa: Cape Town: Emavundleni CRS</b>
Week 177 (Injection #23)	266/1338 (19.9%)	9/40 (22.5%)	0/55 (0.0%)	9/61 (14.8%)	0/38 (0.0%)	20/74 (27.0%)	0/86 (0.0%)
Week 185 (Injection #24)	145/1058 (13.7%)	7/32 (21.9%)	0/47 (0.0%)	6/33 (18.2%)	0/24 (0.0%)	4/55 (7.3%)	0/70 (0.0%)
<hr/>							
Number of All Visits Completed	64047/81525 (78.6%)	1748/2052 (85.2%)	1504/1827 (82.3%)	2535/3092 (82.0%)	2003/2709 (73.9%)	4569/5469 (83.5%)	4219/5605 (75.3%)

<sup>1</sup> Inappropriately enrolled participants are excluded.

<sup>2</sup> Retention at a visit is defined as the number (and %) of participants who completed the visit divided by the number of participants who are expected (visit window has closed), plus any participants who have completed the visit prior to their window closure. The denominator includes participants who are alive, HIV uninfected and have not permanently discontinued study product at the time of the visit.

**HPTN 084 – A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women**  
**Atlas Open Report – March 5, 2024**  
**Visit Cutoff Date: March 5, 2024**  
**Table 8 – Retention <sup>2</sup> by Visit and Site**

	<b>South Africa: Cape Town: Stellenbosch University (DTTC-SU) CRS</b>	<b>South Africa: Johannesburg: Ward 21</b>	<b>South Africa: Kwa Zulu Natal: Isipingo CRS</b>	<b>South Africa: Kwa Zulu Natal: Verulam CRS</b>	<b>South Africa: Soweto: Soweto HPTN CRS</b>	<b>Swaziland: Siteki: Swaziland Prevention Center</b>	<b>Uganda: Entebbe: UVRI-IAVI</b>
Week 177 (Injection #23)	5/43 (11.6%)	24/101 (23.8%)	6/21 (28.6%)	9/34 (26.5%)	39/96 (40.6%)	0/32 (0.0%)	8/57 (14.0%)
Week 185 (Injection #24)	0/32 (0.0%)	15/89 (16.9%)	6/17 (35.3%)	8/29 (27.6%)	32/94 (34.0%)	0/16 (0.0%)	0/40 (0.0%)
<b>Number of All Visits Completed</b>	<b>2357/3621 (65.1%)</b>	<b>3994/5110 (78.2%)</b>	<b>3382/4009 (84.4%)</b>	<b>2977/3619 (82.3%)</b>	<b>3884/4565 (85.1%)</b>	<b>3054/3861 (79.1%)</b>	<b>3260/4581 (71.2%)</b>

<sup>1</sup> Inappropriately enrolled participants are excluded.

<sup>2</sup> Retention at a visit is defined as the number (and %) of participants who completed the visit divided by the number of participants who are expected (visit window has closed), plus any participants who have completed the visit prior to their window closure. The denominator includes participants who are alive, HIV uninfected and have not permanently discontinued study product at the time of the visit.

**HPTN 084 – A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women**  
**Atlas Open Report – March 5, 2024**  
**Visit Cutoff Date: March 5, 2024**  
**Table 8 – Retention <sup>2</sup> by Visit and Site**

	<b>Uganda: Kampala: Baylor-Uganda CRS</b>	<b>Uganda: Kampala: MU-JHU Research Collaboration CRS</b>	<b>Zimbabwe: Chitungwiza: Seke South CRS</b>	<b>Zimbabwe: Chitungwiza: St.Mary's CRS</b>	<b>Zimbabwe: Chitungwiza: Zengeza CRS</b>	<b>Zimbabwe: Harare: Parirenyatwa CRS</b>	<b>Zimbabwe: Harare: Spilhaus CRS</b>
Week 177 (Injection #23)	11/84 (13.1%)	13/63 (20.6%)	6/62 (9.7%)	22/93 (23.7%)	40/115 (34.8%)	30/106 (28.3%)	15/77 (19.5%)
Week 185 (Injection #24)	0/66 (0.0%)	1/44 (2.3%)	2/49 (4.1%)	18/79 (22.8%)	26/102 (25.5%)	20/84 (23.8%)	0/56 (0.0%)
<hr/>							
Number of All Visits Completed	3696/5320 (69.5%)	3849/4886 (78.8%)	3151/4173 (75.5%)	3517/4481 (78.5%)	3708/4547 (81.5%)	3469/4217 (82.3%)	3171/3781 (83.9%)

<sup>1</sup> Inappropriately enrolled participants are excluded.

<sup>2</sup> Retention at a visit is defined as the number (and %) of participants who completed the visit divided by the number of participants who are expected (visit window has closed), plus any participants who have completed the visit prior to their window closure. The denominator includes participants who are alive, HIV uninfected and have not permanently discontinued study product at the time of the visit.

Source: SCHARP (Anusha) – /trials/hptn/p084/analysis/atlas/code/open/t\_retention.sas, SAS Version 9.4 (05MAR2024,19:59)